Nvidia Extends AI Reach In Europe With Alliances Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent.
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Why Novo Nordisk Stock Just Popped Novo Nordisk stock has multiple catalysts that could soon reverse is slide.
2 Weight Loss Drug Stocks That Are Screaming Buys in June These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.
What's Going On With Novo Nordisk Shares Today? Shares of Novo Nordisk Inc. (
NYSE: NVO ) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney cancer.
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation NOVO-NORDISK (
NYSE:NVO ) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks.
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
